Literature DB >> 1015907

A comparison of skeletal, cardiac, and smooth muscle actions of dantrolene sodium--a skeletal muscle relaxant.

K O Ellis, J L Butterfield, F L Wessels, J F Carpenter.   

Abstract

Dantroline sodium, a skeletal muscle relaxant, has been proposed to inhibit the relase of Ca++ from the sarcoplasmic reticulum. Such a mechanism suggests that other muscle contractile systems operating with the same Ca++ denominator should also be affected by the drug. In the present studies dantrolene sodium effects on smooth, cardiac and skeletal muscle have been evaluated with in situ and in vitro techniques. In anesthetized dogs in situ skeletal muscle contractions were inhibitied in a dose-dependent manner, but cardiac muscle contractions were not. Effects on intestinal smooth muscle responses were highly variable and of short duration. In vitro, ED50 values were developed with dantrolene sodium (0.15-120 mg/l) in DMSO for each tissue. Skeletal muscle was the most sensitive (ED50 = 4.1 mg/l), cardiac muscle contractions were not inhibited by the drug and intestinal smooth muscle (ED50 = 59.0 mg/l) was approximately 1/14 as sensitive as skeletal muscle. It is concluded that skeletal muscle is uniquely sensitive to dantrolene sodium. A hypothesis for this specific action is offered.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1015907

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  13 in total

Review 1.  Dantrolene.

Authors:  B A Britt
Journal:  Can Anaesth Soc J       Date:  1984-01

2.  Inotropic and electrophysiological effects of dantrolene on guinea-pig papillary muscle.

Authors:  P Honerjäger; N Alischewski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-04       Impact factor: 3.000

Review 3.  Spasticity and drug therapy.

Authors:  E W Wuis
Journal:  Pharm Weekbl Sci       Date:  1987-10-16

4.  The action of dantrolene sodium on individual fast and slow motor units of the rat anaesthetized with urethane.

Authors:  G C Leslie; N J Part
Journal:  Br J Pharmacol       Date:  1984-02       Impact factor: 8.739

5.  Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

Authors:  B A Britt; E Scott; W Frodis; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1984-03

Review 6.  Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity.

Authors:  A Ward; M O Chaffman; E M Sorkin
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

7.  Effects of some organic calcium antagonists and other procedures affecting Ca2+ Translocation on KCl-induced contractions in the rat vas deferens.

Authors:  D W Hay; R M Wadsworth
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

8.  Dantrolene suppresses spontaneous Ca2+ release without altering excitation-contraction coupling in cardiomyocytes of aged mice.

Authors:  Timothy L Domeier; Cale J Roberts; Anne K Gibson; Laurin M Hanft; Kerry S McDonald; Steven S Segal
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-07-18       Impact factor: 4.733

9.  Successful use of dantrolene sodium in human malignant hyperthermia syndrome: a case report.

Authors:  C M Friesen; J B Brodsky; M F Dillingham
Journal:  Can Anaesth Soc J       Date:  1979-07

10.  Muscle relaxant properties of the identified metabolites of dantrolene.

Authors:  K O Ellis; F L Wessels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978 Jan-Feb       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.